Elliot Zemel was appointed as Director at CANNAPHARMARX, INC..
“Messrs. Constantine Nkafu, Company’s interim CEO, and Elliot Zemel, have now been appointed to the Board.”
CANNAPHARMARX, INC. — fact timeline
Source-grounded facts extracted from CANNAPHARMARX, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Constantine Nkafu was appointed as Director at CANNAPHARMARX, INC..
“Mr. Nkafu was also appointed to the Company’s Board”
Constantine Nkafu was appointed as Interim Chief Executive Officer at CANNAPHARMARX, INC..
“The Board appointed Constantine Nkafu to serve as the Company’s interim CEO.”
CANNAPHARMARX, INC. engaged Barzily & Co. as its auditor.
“On Friday November 29, 2024, CannaPharmaRX, Inc. (the “Company”, “we”, “us”, “our”) engaged with a new auditor, Barzily & Co. (“Barzily”) to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2024.”
GreenGrowth CPAs resigned as auditor of CANNAPHARMARX, INC..
“On Thursday November 14, 2024, CannaPharmaRX, Inc.’s (the “Company”, “we”, “us”, “our”) auditor, GreenGrowth CPAs (“GreenGrowth”) resigned from their engagement as our auditor effective November 14, 2024.”
Dean Medwid resigned as Chief Executive Officer at CANNAPHARMARX, INC..
“Dean Medwid stepped down as the Chief Executive Officer (“CEO”) of CannaPharmaRX, Inc. (the “Company”) for personal reasons.”
CANNAPHARMARX, INC. entered into Supply Agreement with D.N.S. Cantek 2019 Ltd. (effective 2024-02-12).
“On February 12, 2024, CannaPharmaRX, Inc. (the “Company,” “we,” “our,” or “us”), entered into a Supply Agreement (the “Supply Agreement”) by and among us and D.N.S. Cantek 2019 Ltd., an Israeli limited corporation (the “Cantek”)”
CANNAPHARMARX, INC. completed an acquisition involving Amir Tal and Koze Investments LLC for shares of our Class C Convertible Preferred Stock, par value $1.00 per share, each share of which is convertible into shares of our Common Stock, which represen (closed 2023-11-22).
“us to all of the profits and losses of LTB. Consideration due to the Sellers under the Transaction consists of shares of our Class C Convertible Preferred Stock, par value $1.00 per share, each share of which is convertible into shares of our Common Stock, which represents a 33% ownership interest based on our fully-diluted capitalization immediately”
CANNAPHARMARX, INC. entered into Amended and Restated Membership Interest Purchase Agreement with Amir Tal and Koze Investments LLC (effective 2023-11-22).
“On November 22, 2023, CannaPharmaRX, Inc. (the “Company,” “we,” “our,” or “us”), entered into an Amended and Restated Membership Interest Purchase Agreement (the “Purchase Agreement”) by and among us and Amir Tal and Koze Investments LLC (the “Sellers”) whereby we acquired all of the Class B Member Interests in LTB Management, LLC”
CANNAPHARMARX, INC. engaged GreenGrowth CPAs as its auditor.
“On November 3, 2023, we engaged GreenGrowth CPAs (“GreenGrowth”) as our new independent registered public accountant for the fiscal year ending December 31, 2023 and to provide services with respect to the filing of our 10-Q for the period ending September 30, 2023.”
CANNAPHARMARX, INC. dismissed BF Borgers CPA PC as its auditor.
“On November 6, 2023, CannaPharmaRX, Inc. (the “Company”, “we”, “us”) terminated our engagement with our independent registered public accounting firm, BF Borgers CPA PC (“Borgers”), effective November 6, 2023.”
Oliver Foeste was appointed as Chief Financial Officer at CANNAPHARMARX, INC..
“Effective October 13, 2023, our Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer.”
John Cassels departed as Chief Financial Officer at CANNAPHARMARX, INC..
“Effective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc.”
Anthony Michael Panek was appointed as Director at CANNAPHARMARX, INC..
“On August 15th, 2023, the remaining members of the Board appointed Messrs. Adam Mindle and Anthony Michael Panek as members of the Board”
Adam Mindle was appointed as Director at CANNAPHARMARX, INC..
“On August 15th, 2023, the remaining members of the Board appointed Messrs. Adam Mindle and Anthony Michael Panek as members of the Board”
Mark Branson resigned as Director at CANNAPHARMARX, INC..
“On March 23, 2023, Mark Branson informed the Board of Directors (the “Board”) of CannaPharmaRx, Inc. (the “Company”) that he intends to resign as a member of the Board effective immediately.”
Dean Medwid was appointed as Chief Executive Officer at CANNAPHARMARX, INC..
“On June 1, 2023, the Company’s Board of Directors appointed Dean Medwid as Chief Executive Officer.”
Dominic Colvin departed as Chief Executive Officer at CANNAPHARMARX, INC..
“Dominic Colvin stepped down as the Chief Executive Officer (“CEO”) of CannPharmaRX, Inc. (the “Company”) effective June 1, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.